2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMHTZ3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMBUQ3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMWTC3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMGRM3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMSPL3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCBC3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMGGC3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMRDR3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCGC3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMTFM3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMLGK3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMBLB3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMHFN3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCPC3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCEJ3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID1


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID2


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID4


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID5


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID6


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY4


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY5


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY6


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY7


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY8


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY9


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY11


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY12


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY16


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SPC3


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SPC9


2000;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SPC10


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMOST3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMWEK3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMREA3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMDWC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMEMU3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMAPE3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMHPE3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMLBC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMNOS3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMMPG3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMWTD3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMPWD3D


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMSWN3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMGOO3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMEMG3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCBG3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMUPG3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMRED3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMACO3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMTTE3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCRC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMTTR3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMSCQ3N


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCAQ3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMMNQ3L


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMBTF3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCOF3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMHPA3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCPA3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMWPA3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMBLP3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMSFP3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMKAP3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCHI3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMMKP3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMLAP3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMIPF3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCPF3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMGUI3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMHTZ3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMWTC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMGRM3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMSPL3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCBC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMGGC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMRDR3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCGC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMLGK3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMBLB3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMHFN3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCPC3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;OMCEJ3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;HYBRID5


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY3


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY4


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY5


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY6


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY7


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY8


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY9


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY10


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY11


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY12


2000;Human leukocyte elastase;Turkey ovomucoid third domain;294;;;;;;;;;;;;;SEMSY16


5F4E_A_B;WA148A;WA127A;COR;;5F4E_A_B;n.b;;5.9E-08;5.9E-08;27309818;Sperm-egg fusion protein Izumo;Sperm-egg fusion protein Juno;293;;;;;;;;;;;;;;BI;2


4WND_A_B;1.3E-07;1.3E-07;2.4E-09;2.4E-09;22074847;G-protein-signaling modulator 2 (LGN);Protein inscuteable homolog (INSC);298;;;;;;;;;;;;;;SPR;2


4WND_A_B;1.9E-08;1.9E-08;2.4E-09;2.4E-09;22074847;G-protein-signaling modulator 2 (LGN);Protein inscuteable homolog (INSC);298;;;;;;;;;;;;;;SPR;2


4WND_A_B;n.b;;2.4E-09;2.4E-09;22074847;G-protein-signaling modulator 2 (LGN);Protein inscuteable homolog (INSC);298;;;;;;;;;;;;;;SPR;2


4WND_A_B;4.3E-07;4.3E-07;2.4E-09;2.4E-09;22074847;G-protein-signaling modulator 2 (LGN);Protein inscuteable homolog (INSC);298;;;;;;;;;;;;;;SPR;2


4WND_A_B;6.2E-08;6.2E-08;2.4E-09;2.4E-09;22074847;G-protein-signaling modulator 2 (LGN);Protein inscuteable homolog (INSC);298;;;;;;;;;;;;;;SPR;2


4WND_A_B;4.8E-09;4.8E-09;2.4E-09;2.4E-09;22074847;G-protein-signaling modulator 2 (LGN);Protein inscuteable homolog (INSC);298;;;;;;;;;;;;;;SPR;2


4WND_A_B;4.8E-06;4.8E-06;1.1E-07;1.1E-07;22074847;G-protein-signaling modulator 2 (LGN);FERM and PDZ domain-containing protein 1 (FRMPD1) peptide;298;;;;;;;;;;;;;;SPR;2


4WND_A_B;1.6E-07;1.6E-07;1.1E-07;1.1E-07;22074847;G-protein-signaling modulator 2 (LGN);FERM and PDZ domain-containing protein 1 (FRMPD1) peptide;298;;;;;;;;;;;;;;SPR;2


4WND_A_B;5.2E-06;5.2E-06;1.1E-07;1.1E-07;22074847;G-protein-signaling modulator 2 (LGN);FERM and PDZ domain-containing protein 1 (FRMPD1) peptide;298;;;;;;;;;;;;;;SPR;2


4G2V_A_B;6.5E-06;6.5E-06;5.8E-08;5.8E-08;22074847;G-protein-signaling modulator 2 (LGN);FERM and PDZ domain-containing protein 4 (FRMPD4);298;;;;;;;;;;;;;;SPR;2


4G2V_A_B;5.6E-08;5.6E-08;5.8E-08;5.8E-08;22074847;G-protein-signaling modulator 2 (LGN);FERM and PDZ domain-containing protein 4 (FRMPD4);298;;;;;;;;;;;;;;SPR;2


4G2V_A_B;3.9E-05;3.9E-05;5.8E-08;5.8E-08;22074847;G-protein-signaling modulator 2 (LGN);FERM and PDZ domain-containing protein 4 (FRMPD4);298;;;;;;;;;;;;;;SPR;2


1JCK_A_B;5.24E-06;5.24E-06;5.24E-06;5.24E-06;18275829;HLA-A2 plus flu peptide;JM22 TCR;298;;;;;;;;;-23;-18;-50.3;-33.5;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;9.5E-06;9.5E-06;2.4E-08;2.4E-08;24550723;HLA-A2 plus MART-1 peptide;DMF5 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;3.2E-06;3.2E-06;4E-09;4E-09;23805144;HLA-A2 plus tax peptide;A6 TCR;298(assumed);2.3E+04;2.3E+04;4.5E+04;4.5E+04;7.4E-02;7.4E-02;1.8E-04;1.8E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;1.9E-06;1.9E-06;4E-09;4E-09;23805144;HLA-A2 plus tax peptide;A6 TCR;298(assumed);1.8E+04;1.8E+04;4.5E+04;4.5E+04;3.5E-02;3.5E-02;1.8E-04;1.8E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;1.8E-06;1.8E-06;4E-09;4E-09;23805144;HLA-A2 plus tax peptide;A6 TCR;298(assumed);2.3E+04;2.3E+04;4.5E+04;4.5E+04;4.1E-02;4.1E-02;1.8E-04;1.8E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;9.4E-09;9.4E-09;4E-09;4E-09;23805144;HLA-A2 plus tax peptide;A6 TCR;298(assumed);2.3E+04;2.3E+04;4.5E+04;4.5E+04;5.2E-04;5.2E-04;1.8E-04;1.8E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;4.4E-09;4.4E-09;4E-09;4E-09;23805144;HLA-A2 plus tax peptide;A6 TCR;298(assumed);5.5E+04;5.5E+04;4.5E+04;4.5E+04;2.2E-04;2.2E-04;1.8E-04;1.8E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;8E-09;8E-09;4E-09;4E-09;23805144;HLA-A2 plus tax peptide;A6 TCR;298(assumed);1.9E+04;1.9E+04;4.5E+04;4.5E+04;1.5E-04;1.5E-04;1.8E-04;1.8E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;9E-07;9E-07;1.2E-06;1.2E-06;22019736;HLA-A2 plus tax peptide;A6 TCR;277;;;;;;;;;4.4;5.9;44;48;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;6E-10;6E-10;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;1.4E-04;1.4E-04;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;n.b;;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;4.1E-05;4.1E-05;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;3.1E-05;3.1E-05;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;2.1E-05;2.1E-05;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;3.7E-05;3.7E-05;3.6E-05;3.6E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;6E-10;6E-10;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;1.4E-04;1.4E-04;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;3.6E-05;3.6E-05;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;n.b;;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;4.1E-05;4.1E-05;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;2.1E-05;2.1E-05;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;3.7E-05;3.7E-05;3.1E-05;3.1E-05;23698002;HLA-A2 plus MART-1 peptide;a24b17 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;1E-06;1E-06;7E-06;7E-06;17825839;HLA-A2 plus P1049 peptide;AHIII TCR;298;;;;;;;;;-3.9;-0.6;14.8;21.1;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1JCK_A_B;9.1E-07;9.1E-07;n.b;;10435578;HLA-A2 plus tax peptide;A6 TCR;298;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;TCR/pMHC;TCR/pMHC;n.b;;2E-09;2E-09;24196962;HLA-A2 plus telomerase peptide;ILA1 TCR;298;;;;;;;;;;;;;;SPR;2


INT;TCR/pMHC;TCR/pMHC;1.9E-05;1.9E-05;2E-09;2E-09;24196962;HLA-A2 plus telomerase peptide;ILA1 TCR;298;3.9E+03;3.9E+03;8E+04;8E+04;7.3E-02;7.3E-02;1.6E-04;1.6E-04;;;;;Mismatch in the paper between kinetics and affinity

which reports kon as 3.9e5. Value reported here is two orders of magnitude lower


SUP;;1QAB_ABCD_E;n.b;;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


INT;;1QAB_ABCD_E;2.2E-07;2.2E-07;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


INT;;1QAB_ABCD_E;6.6E-07;6.6E-07;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


INT;;1QAB_ABCD_E;3.1E-07;3.1E-07;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


SUR;;1QAB_ABCD_E;4.3E-07;4.3E-07;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


COR;;1QAB_ABCD_E;1.64E-06;1.64E-06;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


SUR;;1QAB_ABCD_E;6.23E-06;6.23E-06;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


SUR;;1QAB_ABCD_E;5.81E-06;5.81E-06;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


SUP;;1QAB_ABCD_E;1.12E-06;1.12E-06;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


SUP;;1QAB_ABCD_E;1.8E-07;1.8E-07;3.5E-07;3.5E-07;19021760;Transthyretin;Plasma retinol-binding protein;293;;;;;;;;;;;;;ABCD tetramer has two symmetric binding sites on opposite faces


3SZK_AB_C;NC120A;NC35A;SUR;;3SZK_AB_C;2.1E-08;2.1E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;TC123A;TC38A;SUR;;3SZK_AB_C;8.2E-08;8.2E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;QC124A;QC39A;INT;;3SZK_AB_C;6.2E-08;6.2E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;YC125A;YC40A;RIM;;3SZK_AB_C;2.29E-06;2.29E-06;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;YC126A;YC41A;COR;;3SZK_AB_C;2.61E-06;2.61E-06;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;HC127A;HC42A;INT;;3SZK_AB_C;1.23E-06;1.23E-06;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;FC128A;FC43A;RIM;;3SZK_AB_C;7.2E-07;7.2E-07;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;FC129A;FC44A;COR;;3SZK_AB_C;6.98E-07;6.98E-07;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;NC151A;NC66A;COR;;3SZK_AB_C;2.4E-08;2.4E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;SC154A;SC69A;RIM;;3SZK_AB_C;2.19E-07;2.19E-07;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;TC155A;TC70A;SUP;;3SZK_AB_C;2.03E-07;2.03E-07;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;DC205A;DC120A;RIM;;3SZK_AB_C;5.3E-08;5.3E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;DC206A;DC121A;SUR;;3SZK_AB_C;5.5E-08;5.5E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;GC207A;GC122A;SUR;;3SZK_AB_C;3.2E-08;3.2E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;EC208A;EC123A;SUR;;3SZK_AB_C;7E-08;7E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;EC209A;EC124A;SUR;;3SZK_AB_C;5.5E-08;5.5E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;VC112A;VC27A;INT;;3SZK_AB_C;2E-08;2E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;DC133A;DC48A;SUR;;3SZK_AB_C;2.4E-08;2.4E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;DC136A;DC51A;INT;;3SZK_AB_C;2.4E-08;2.4E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;KC141A;KC56A;SUR;;3SZK_AB_C;2E-08;2E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3SZK_AB_C;KC142A;KC57A;SUR;;3SZK_AB_C;1.6E-08;1.6E-08;1.7E-08;1.7E-08;18984582;Human metHaemoglobin;Iron-regulated surface determinant protein H;283;;;;;;;;;;;;;;SPR;2


3Q8D_A_E;RA203A;RA202A;SUR;;3Q8D_A_E;1.3E-07;1.3E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA203E;RA202E;SUR;;3Q8D_A_E;6.2E-07;6.2E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA210A;RA209A;RIM;;3Q8D_A_E;5.6E-07;5.6E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA210E;RA209E;RIM;;3Q8D_A_E;>1E-05;1E-05;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;FA228A;FA227A;COR;;3Q8D_A_E;1E-07;1E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;FA228D;FA227D;COR;;3Q8D_A_E;>1E-05;1E-05;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA229A;RA228A;SUR;;3Q8D_A_E;1.1E-07;1.1E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA229E;RA228E;SUR;;3Q8D_A_E;4.6E-07;4.6E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA132A;RA131A;SUP;;3Q8D_A_E;>1E-05;1E-05;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA98A;RA97A;SUR;;3Q8D_A_E;1.3E-07;1.3E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


3Q8D_A_E;RA13A;RA12A;SUR;;3Q8D_A_E;1.1E-07;1.1E-07;6E-08;6E-08;21504984;DNA repair protein recO;Single-stranded DNA-binding protein;298(assumed);;;;;;;;;;;;;;FL;2


1XGU_AB_C;FB33L;FB33L;COR;AB/AG;AB/AG;1.22E-07;1.22E-07;5.26E-09;5.26E-09;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.6;-20.9;-10.7;-32.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGU_AB_C;FB33I;FB33I;COR;AB/AG;AB/AG;1.1E-07;1.1E-07;5.26E-09;5.26E-09;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-14;-20.9;-15.1;-32.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGU_AB_C;FB33V;FB33V;COR;AB/AG;AB/AG;7.14E-07;7.14E-07;5.26E-09;5.26E-09;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.2;-20.9;-12.7;-32.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGU_AB_C;FB33A;FB33A;COR;AB/AG;AB/AG;5E-06;5E-06;5.26E-09;5.26E-09;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-9;-20.9;-6.04;-32.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGP_AB_C;AB33F;AB33F;SUP;AB/AG;AB/AG;5.26E-09;5.26E-09;5E-06;5E-06;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-20.9;-9;-32.2;-6.04;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGP_AB_C;AB33L;AB33L;SUP;AB/AG;AB/AG;1.22E-07;1.22E-07;5E-06;5E-06;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.6;-9;-10.7;-6.04;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGP_AB_C;AB33I;AB33I;SUP;AB/AG;AB/AG;1.1E-07;1.1E-07;5E-06;5E-06;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-14;-9;-15.1;-6.04;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGP_AB_C;AB33V;AB33V;SUP;AB/AG;AB/AG;7.14E-07;7.14E-07;5E-06;5E-06;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.2;-9;-12.7;-6.04;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGQ_AB_C;VB33F;VB33F;SUP;AB/AG;AB/AG;5.26E-09;5.26E-09;7.14E-07;7.14E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-20.9;-12.2;-32.2;-12.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGQ_AB_C;VB33L;VB33L;SUP;AB/AG;AB/AG;1.22E-07;1.22E-07;7.14E-07;7.14E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.6;-12.2;-10.7;-12.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGQ_AB_C;VB33I;VB33I;SUP;AB/AG;AB/AG;1.1E-07;1.1E-07;7.14E-07;7.14E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-14;-12.2;-15.1;-12.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGQ_AB_C;VB33A;VB33A;SUP;AB/AG;AB/AG;5E-06;5E-06;7.14E-07;7.14E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-9;-12.2;-6.04;-12.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGR_AB_C;IB33F;IB33F;SUP;AB/AG;AB/AG;5.26E-09;5.26E-09;1.1E-07;1.1E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-20.9;-14;-32.2;-15.1;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGR_AB_C;IB33L;IB33L;SUP;AB/AG;AB/AG;1.22E-07;1.22E-07;1.1E-07;1.1E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.6;-14;-10.7;-15.1;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGR_AB_C;IB33V;IB33V;SUP;AB/AG;AB/AG;7.14E-07;7.14E-07;1.1E-07;1.1E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.2;-14;-12.7;-15.1;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGR_AB_C;IB33A;IB33A;SUP;AB/AG;AB/AG;5E-06;5E-06;1.1E-07;1.1E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-9;-14;-6.04;-15.1;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGT_AB_C;LB33F;LB33F;SUP;AB/AG;AB/AG;5.26E-09;5.26E-09;1.22E-07;1.22E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-20.9;-12.6;-32.2;-10.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGT_AB_C;LB33I;LB33I;SUP;AB/AG;AB/AG;1.1E-07;1.1E-07;1.22E-07;1.22E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-14;-12.6;-15.1;-10.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGT_AB_C;LB33V;LB33V;SUP;AB/AG;AB/AG;7.14E-07;7.14E-07;1.22E-07;1.22E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-12.2;-12.6;-12.7;-10.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


1XGT_AB_C;LB33A;LB33A;SUP;AB/AG;AB/AG;5E-06;5E-06;1.22E-07;1.22E-07;15698573;HyHEL-63 fab;HEW Lysozyme;298;;;;;;;;;-9;-12.6;-6.04;-10.7;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type' and is mutated to another mutant.;ITC;2


4K71_A_BC;GA505E;GA503E;COR;;4K71_A_BC;1.05E-08;1.05E-08;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUP;;4K71_A_BC;2.26E-08;2.26E-08;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;5.01E-08;5.01E-08;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


4K71_A_BC;AA547V;AA545V;INT;;4K71_A_BC;9.26E-08;9.26E-08;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


COR;;4K71_A_BC;3.26E-07;3.26E-07;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;3.68E-07;3.68E-07;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;3.71E-07;3.71E-07;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;3.95E-07;3.95E-07;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;4.2E-07;4.2E-07;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;5.9E-07;5.9E-07;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;1.03E-06;1.03E-06;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


4K71_A_BC;HA464A;HA462A;SUP;;4K71_A_BC;1.77E-08;1.77E-08;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


4K71_A_BC;HA464F;HA462F;SUP;;4K71_A_BC;1.65E-08;1.65E-08;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


4K71_A_BC;HB161A;HB157A;RIM;;4K71_A_BC;8.9E-09;8.9E-09;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


4K71_A_BC;HB161F;HB157F;RIM;;4K71_A_BC;4.1E-09;4.1E-09;3E-09;3E-09;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;5E-06;5E-06;8E-09;8E-09;24120761;Human Serum Albumin;FcRn;298(assumed);5.6E+03;5.6E+03;2.7E+04;2.7E+04;2.8E-02;2.8E-02;2.2E-04;2.2E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


COR;;4K71_A_BC;4.5E-07;4.5E-07;8E-09;8E-09;24120761;Human Serum Albumin;FcRn;298(assumed);5.4E+03;5.4E+03;2.7E+04;2.7E+04;2.4E-03;2.4E-03;2.2E-04;2.2E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUP;;4K71_A_BC;6.4E-08;6.4E-08;8E-09;8E-09;24120761;Human Serum Albumin;FcRn;298(assumed);1.4E+04;1.4E+04;2.7E+04;2.7E+04;9.2E-04;9.2E-04;2.2E-04;2.2E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


4K71_A_BC;AA547V;AA545V;INT;;4K71_A_BC;2.3E-07;2.3E-07;8E-09;8E-09;24120761;Human Serum Albumin;FcRn;298(assumed);1.1E+04;1.1E+04;2.7E+04;2.7E+04;2.7E-03;2.7E-03;2.2E-04;2.2E-04;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


INT;;4K71_A_BC;n.b;;6.2E-06;6.2E-06;24120761;Human Serum Albumin;FcRn;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


COR;;4K71_A_BC;1.3E-04;1.3E-04;6.2E-06;6.2E-06;24120761;Human Serum Albumin;FcRn;298(assumed);1E+03;1E+03;5.2E+03;5.2E+03;1.3E-01;1.3E-01;3.2E-02;3.2E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


SUP;;4K71_A_BC;2.6E-05;2.6E-05;6.2E-06;6.2E-06;24120761;Human Serum Albumin;FcRn;298(assumed);1.7E+03;1.7E+03;5.2E+03;5.2E+03;4.5E-02;4.5E-02;3.2E-02;3.2E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


1MI5_ABC_DE;n.b;;2.22E-05;2.22E-05;24550293;Killer cell immunoglobulin-like receptor 2DS2;HLA-A-11 plus A14 peptide;298;;;;;;;;;;;;;;SPR;2


2OOB_A_B;8.3E-05;8.3E-05;1.75E-07;1.75E-07;20427284;Ubiquitin conjugation factor E4;DSK2;298;;;;;;;;;;;;;Thermodynamic parameters removed due to impossible values reported in paper.;ITC;2


2B0U_AB_C;1.7E-07;1.7E-07;1.3E-09;1.3E-09;22052913;Myostatin;Follistatin-like 3;298;;;;;;;;;;;;;While myostatin appears once in the unit cell

it binds as a symmetrical dimer and thus the dimer must be created using a copy from the adjacent unit cell using the two-fold screw-axis symmetry operation. This is chain A;SPR;2


2B0U_AB_C;2.4E-06;2.4E-06;1.3E-09;1.3E-09;22052913;Myostatin;Follistatin-like 3;298;;;;;;;;;;;;;While myostatin appears once in the unit cell


2B0U_AB_C;1.6E-06;1.6E-06;1.3E-09;1.3E-09;22052913;Myostatin;Follistatin-like 3;298;;;;;;;;;;;;;While myostatin appears once in the unit cell


2B0U_AB_C;1.2E-07;1.2E-07;1.3E-09;1.3E-09;22052913;Myostatin;Follistatin-like 3;298;;;;;;;;;;;;;While myostatin appears once in the unit cell


2B0U_AB_C;5.6E-08;5.6E-08;1.3E-09;1.3E-09;22052913;Myostatin;Follistatin-like 3;298;;;;;;;;;;;;;While myostatin appears once in the unit cell


2B0U_AB_C;4.1E-07;4.1E-07;1.3E-09;1.3E-09;22052913;Myostatin;Follistatin-like 3;298;;;;;;;;;;;;;While myostatin appears once in the unit cell


5M2O_A_B;1.3E-11;1.3E-11;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;2.8E+06;2.8E+06;2.1E+06;2.1E+06;3.5E-05;3.5E-05;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;1.4E-11;1.4E-11;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;2E+06;2E+06;2.1E+06;2.1E+06;2.9E-05;2.9E-05;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;n.b.;;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;6.4E-11;6.4E-11;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;4.6E+06;4.6E+06;2.1E+06;2.1E+06;2.9E-04;2.9E-04;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;5.6E-10;5.6E-10;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;5.6E+05;5.6E+05;2.1E+06;2.1E+06;3.1E-04;3.1E-04;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;1.3E-08;1.3E-08;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;4E+06;4E+06;2.1E+06;2.1E+06;5.4E-02;5.4E-02;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;5.4E-08;5.4E-08;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;1.2E+06;1.2E+06;2.1E+06;2.1E+06;6.7E-02;6.7E-02;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;3E-11;3E-11;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;9.1E+06;9.1E+06;2.1E+06;2.1E+06;2.7E-04;2.7E-04;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;3.8E-08;3.8E-08;2E-11;2E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;1.7E+06;1.7E+06;2.1E+06;2.1E+06;6.4E-02;6.4E-02;4.2E-05;4.2E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;1.3E-11;1.3E-11;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;2.8E+06;2.8E+06;2E+06;2E+06;3.5E-05;3.5E-05;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;2E-11;2E-11;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;2.1E+06;2.1E+06;2E+06;2E+06;4.2E-05;4.2E-05;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;n.b.;;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;6.4E-11;6.4E-11;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;4.6E+06;4.6E+06;2E+06;2E+06;2.9E-04;2.9E-04;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;5.6E-10;5.6E-10;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;5.6E+05;5.6E+05;2E+06;2E+06;3.1E-04;3.1E-04;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;1.3E-08;1.3E-08;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;4E+06;4E+06;2E+06;2E+06;5.4E-02;5.4E-02;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;5.4E-08;5.4E-08;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;1.2E+06;1.2E+06;2E+06;2E+06;6.7E-02;6.7E-02;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;3E-11;3E-11;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;9.1E+06;9.1E+06;2E+06;2E+06;2.7E-04;2.7E-04;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


5M2O_A_B;3.8E-08;3.8E-08;1.4E-11;1.4E-11;25855788;A. cellulolyticus scaC cohesin;A. cellulolyticus scaB dockerin;308;1.7E+06;1.7E+06;2E+06;2E+06;6.4E-02;6.4E-02;2.9E-05;2.9E-05;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'


COR;Pr/PI;Pr/PI;1.06E-12;1.06E-12;5.2E-12;5.2E-12;23892073;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


COR;Pr/PI;Pr/PI;1.07E-07;1.07E-07;5.2E-12;5.2E-12;23892073;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


COR;Pr/PI;Pr/PI;9.09E-13;9.09E-13;5.2E-12;5.2E-12;23892073;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


RIM;Pr/PI;Pr/PI;1.11E-06;1.11E-06;5.2E-12;5.2E-12;23892073;Bovine alpha-chymotrypsin;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


COR;Pr/PI;Pr/PI;2.63E-14;2.63E-14;1.77E-11;1.77E-11;23892073;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


RIM;Pr/PI;Pr/PI;4E-10;4E-10;1.77E-11;1.77E-11;23892073;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


COR;Pr/PI;Pr/PI;1.64E-14;1.64E-14;1.77E-11;1.77E-11;23892073;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


RIM;Pr/PI;Pr/PI;2.08E-11;2.08E-11;1.77E-11;1.77E-11;23892073;Streptomyces griseus proteinase B;Turkey ovomucoid third domain;295;;;;;;;;;;;;;;FL;2


SUR;;2VN5_A_B;1.54E-09;1.54E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-19.3;-20.8;-22.2;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes

only one of which appears in the crystal structure.;ITC;2


COR;;2VN5_A_B;1.67E-09;1.67E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-19.8;-20.8;-24.1;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes

only one of which appears in the crystal structure.;ITC;2


SUP;;2VN5_A_B;7.41E-09;7.41E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-18.2;-20.8;-21.8;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;8.33E-09;8.33E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-18.2;-20.8;-21.9;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;8.62E-10;8.62E-10;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-21.5;-20.8;-28.2;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;1E-09;1E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-22.4;-20.8;-31.3;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;2.04E-07;2.04E-07;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-14;-20.8;-12.9;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;1.22E-07;1.22E-07;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-23.2;-20.8;-39.3;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;2.72E-09;2.72E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-22.3;-20.8;-33.1;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;4.72E-09;4.72E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-26.7;-20.8;-48.7;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;1.36E-08;1.36E-08;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-20.2;-20.8;-29.6;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


RIM;;2VN5_A_B;2.35E-09;2.35E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-22.1;-20.8;-32.3;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


only one of which appears in the crystal structure.;ITC;2

SUP;;2VN5_A_B;1.57E-08;1.57E-08;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-19.5;-20.8;-27.6;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;4.72E-07;4.72E-07;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-14.6;-20.8;-18.5;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes

only one of which appears in the crystal structure.;ITC;2


COR;;2VN5_A_B;1.75E-07;1.75E-07;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-15.4;-20.8;-19;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;5E-06;5E-06;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-15.4;-20.8;-25.7;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes

only one of which appears in the crystal structure.;ITC;2


COR;;2VN5_A_B;1.26E-09;1.26E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-24.2;-20.8;-37.7;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;1.61E-05;1.61E-05;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-11.2;-20.8;-16.3;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


RIM;;2VN5_A_B;5.21E-08;5.21E-08;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-19.8;-20.8;-31;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;1.8E-09;1.8E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-18;-20.8;-18.5;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;1.29E-09;1.29E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-17.5;-20.8;-16.1;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


COR;;2VN5_A_B;8.62E-09;8.62E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-18.6;-20.8;-23.5;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


SUR;;2VN5_A_B;4.88E-09;4.88E-09;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-22.6;-20.8;-35.1;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


SUP;;2VN5_A_B;4.35E-06;4.35E-06;1E-09;1E-09;18445585;C. cellulolyticum cipC cohesin;C. cellulolyticum celCCA dockerin;308;;;;;;;;;-18.1;-20.8;-34.1;-26.2;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type'. The interaction has two distinct binding modes


4NZW_A_B;2.28E-08;2.28E-08;9.12E-09;9.12E-09;23434407;MO25;MST4;298(assumed);;;;;;;;;;;;;Affinities are first binding event from BI data fitted with 2:1 heterogeneous ligand model;BI;2


4NZW_A_B;7.79E-08;7.79E-08;9.12E-09;9.12E-09;23434407;MO25;MST4;298(assumed);;;;;;;;;;;;;Affinities are first binding event from BI data fitted with 2:1 heterogeneous ligand model;BI;2


4NZW_A_B;5.17E-08;5.17E-08;9.12E-09;9.12E-09;23434407;MO25;MST4;298(assumed);;;;;;;;;;;;;Affinities are first binding event from BI data fitted with 2:1 heterogeneous ligand model;BI;2


4NZW_A_B;n.b;;9.12E-09;9.12E-09;23434407;MO25;MST4;298(assumed);;;;;;;;;;;;;Affinities are first binding event from BI data fitted with 2:1 heterogeneous ligand model;BI;2


4NZW_A_B;1.87E-08;1.87E-08;9.12E-09;9.12E-09;23434407;MO25;MST4;298(assumed);;;;;;;;;;;;;Affinities are first binding event from BI data fitted with 2:1 heterogeneous ligand model;BI;2


RIM;AB/AG;AB/AG;<1.4E-10;1.4E-10;2.9E-09;2.9E-09;10543973;Fab-12;VEGF;298;3.6E+04;3.6E+04;4.1E+04;4.1E+04;<5E-06;5E-06;1.2E-04;1.2E-04;;;;;Mutations from crystal structure to an affinity matured variant of fab-12. An additional T to L mutations also appears in a crystallographically unresolved region.;SPR;2


RIM;AB/AG;AB/AG;1.1E-09;1.1E-09;1.3E-08;1.3E-08;10543973;Fab-12;VEGF;310;5.4E+04;5.4E+04;5.1E+04;5.1E+04;5.9E-06;5.9E-06;6.6E-04;6.6E-04;;;;;Mutations from crystal structure to an affinity matured variant of fab-12. An additional T to L mutations also appears in a crystallographically unresolved region.;SPR;2


RIM;AB/AG;AB/AG;2.9E-09;2.9E-09;<1.4E-10;1.4E-10;10543973;Fab-12;VEGF;298;4.1E+04;4.1E+04;3.6E+04;3.6E+04;1.2E-04;1.2E-04;<5E-06;5E-06;;;;;Back mutation from affinity-matured crystal structure to precursor fab-12. The matured is taken as 'wild-type'. An additional L to T mutations also appears in a crystallographically unresolved region.;SPR;2


RIM;AB/AG;AB/AG;1.3E-08;1.3E-08;1.1E-10;1.1E-10;10543973;Fab-12;VEGF;310;5.1E+04;5.1E+04;5.4E+04;5.4E+04;6.6E-04;6.6E-04;5.9E-06;5.9E-06;;;;;Back mutation from affinity-matured crystal structure to precursor fab-12. The matured is taken as 'wild-type'. An additional L to T mutations also appears in a crystallographically unresolved region.;SPR;2


as these solvent exposed residues and exist only to enhance expression. Mutations from fab-12;SPR;2


as these solvent exposed residues and exist only to enhance expression. Mutations from affinity matured fab-12;SPR;2


and the mutations revert to the unmatured fab.;KinExA;2

RIM;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper


SUP;AB/AG;AB/AG;4.05E-08;4.05E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;5.45E-09;5.45E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


INT;AB/AG;AB/AG;6.91E-09;6.91E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;6.54E-09;6.54E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;6.91E-09;6.91E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;7.52E-09;7.52E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;2.76E-09;2.76E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;7.14E-09;7.14E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;1.01E-08;1.01E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


SUR;AB/AG;AB/AG;7.59E-09;7.59E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;6.3E-09;6.3E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


COR;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;2.24E-08;2.24E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


RIM;AB/AG;AB/AG;4.62E-09;4.62E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


INT;AB/AG;AB/AG;9.14E-09;9.14E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


INT;AB/AG;AB/AG;6.69E-09;6.69E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


2B2X_HL_A;EH64K;EH64K;SUR;AB/AG;AB/AG;1.12E-09;1.12E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


2B2X_HL_A;VH50T;VH50T;SUP;AB/AG;AB/AG;1.7E-09;1.7E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


2B2X_HL_A;YL52E;YL52E;RIM;AB/AG;AB/AG;1E-09;1E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';KinExA;2


COR;AB/AG;AB/AG;5E-08;5E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper

and the mutations revert to the unmatured fab.;ELISA;2


COR;AB/AG;AB/AG;5.67E-08;5.67E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;6.07E-08;6.07E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;3.27E-08;3.27E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;3.54E-08;3.54E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;2.58E-08;2.58E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;7.73E-08;7.73E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;8.5E-07;8.5E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;2.13E-08;2.13E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;5.86E-09;5.86E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;2E-09;2E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;2.13E-07;2.13E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;1.21E-07;1.21E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;4.25E-07;4.25E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;8.5E-07;8.5E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;n.b.;;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;1.21E-07;1.21E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;2.02E-08;2.02E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;2.83E-07;2.83E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;2.66E-08;2.66E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;2.02E-08;2.02E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;8.5E-08;8.5E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;6.07E-08;6.07E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;n.b.;;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;2.83E-07;2.83E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;3.4E-08;3.4E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;1.01E-08;1.01E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUR;AB/AG;AB/AG;4.6E-09;4.6E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;n.b.;;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;2.83E-08;2.83E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;2.13E-07;2.13E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;1.98E-08;1.98E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;1.7E-07;1.7E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;n.b.;;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;3.7E-08;3.7E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;1.77E-08;1.77E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


SUP;AB/AG;AB/AG;8.5E-07;8.5E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;1.21E-07;1.21E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;n.b.;;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;3.04E-08;3.04E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;8.5E-07;8.5E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;1.2E-08;1.2E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;2.18E-08;2.18E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;8.5E-07;8.5E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;2.83E-07;2.83E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;9.44E-08;9.44E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


INT;AB/AG;AB/AG;1.42E-07;1.42E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;7.08E-08;7.08E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;1.77E-08;1.77E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;8.5E-09;8.5E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


COR;AB/AG;AB/AG;1.42E-07;1.42E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;n.b.;;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;2.13E-07;2.13E-07;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;7.08E-08;7.08E-08;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;2.63E-09;2.63E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


RIM;AB/AG;AB/AG;2E-09;2E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


2B2X_HL_A;EH64K;EH64K;SUR;AB/AG;AB/AG;1.7E-09;1.7E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


2B2X_HL_A;VH50T;VH50T;SUP;AB/AG;AB/AG;1.36E-09;1.36E-09;1.46E-09;1.46E-09;16597831;AQC2 fab;Integrin alpha-1;298(assumed);;;;;;;;;;;;;Crystal structure is the affinity matured fab reported in the paper. This is taken as 'wild-type';ELISA;2


TG123C not included as is disordered is crystal structure.;SPR;2


INT;AB/AG;AB/AG;1.36E-10;1.36E-10;1.25E-10;1.25E-10;17173035;AR2 mab;BoNT/A1;296;;;;;;;;;;;;;'wild-type' is affinity matured AR2. This is 'back-mutation' to the parent mab.;KinExA;2


3SE4_B_C;7E-09;7E-09;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;1.5E-02;1.5E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient

and the ddG and kinetic data is for the wild-type. However

the three mutations in the HEQ varient are on the opposite side of IFN2a from the IFNAR2 binding site

and have no affect on the kinetics or affinity of the interactions [17310065


3SE4_B_C;5.5E-08;5.5E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;1.14E-01;1.14E-01;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.4E-08;2.4E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.9E+06;1.9E+06;2.1E+06;2.1E+06;4.6E-02;4.6E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1E-08;1E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.3E+06;2.3E+06;2.1E+06;2.1E+06;2.2E-02;2.2E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;5E-06;5E-06;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.3E-08;2.3E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.3E+06;1.3E+06;2.1E+06;2.1E+06;3E-02;3E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.9E-08;1.9E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;4.1E-02;4.1E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2E-08;2E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.8E+06;1.8E+06;2.1E+06;2.1E+06;3.7E-02;3.7E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.5E-08;1.5E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;3.1E-02;3.1E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1E-08;1E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;2.1E-02;2.1E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.2E-08;1.2E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.9E+06;1.9E+06;2.1E+06;2.1E+06;2.4E-02;2.4E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.8E-08;1.8E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.9E+06;1.9E+06;2.1E+06;2.1E+06;3.4E-02;3.4E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;9E-09;9E-09;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;2.1E-02;2.1E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.6E-08;1.6E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.4E+06;1.4E+06;2.1E+06;2.1E+06;2.3E-02;2.3E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8E-09;8E-09;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.4E+06;2.4E+06;2.1E+06;2.1E+06;1.9E-02;1.9E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.7E-08;3.7E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);9E+05;9E+05;2.1E+06;2.1E+06;3.3E-02;3.3E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.1E-08;1.1E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.8E+06;1.8E+06;2.1E+06;2.1E+06;2.1E-02;2.1E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.3E-07;1.3E-07;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.2E-08;2.2E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.1E+06;2.1E+06;2.1E+06;2.1E+06;4.7E-02;4.7E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.7E-08;1.7E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.6E+06;2.6E+06;2.1E+06;2.1E+06;5.3E-02;5.3E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-08;3E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.3E+06;1.3E+06;2.1E+06;2.1E+06;4E-02;4E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.4E-08;1.4E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.2E+06;2.2E+06;2.1E+06;2.1E+06;3.2E-02;3.2E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.9E-08;1.9E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.8E+06;1.8E+06;2.1E+06;2.1E+06;3.4E-02;3.4E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.4E-08;3.4E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.6E+06;1.6E+06;2.1E+06;2.1E+06;5.5E-02;5.5E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.7E-08;1.7E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2E+06;2E+06;2.1E+06;2.1E+06;3.3E-02;3.3E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.9E-08;2.9E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.9E+06;1.9E+06;2.1E+06;2.1E+06;5.5E-02;5.5E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;7E-09;7E-09;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.2E+06;2.2E+06;2.1E+06;2.1E+06;1.6E-02;1.6E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.5E-08;3.5E-08;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.8E+06;1.8E+06;2.1E+06;2.1E+06;6.3E-02;6.3E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;9E-09;9E-09;1E-08;1E-08;10556041;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1.8E+06;1.8E+06;2.1E+06;2.1E+06;1.7E-02;1.7E-02;2E-02;2E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4E-09;4E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3.7E+06;3.7E+06;3.7E+06;3.7E+06;1.5E-02;1.5E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.6E-09;2.6E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3.2E+06;3.2E+06;3.7E+06;3.7E+06;8E-03;8E-03;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.69E-08;1.69E-08;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3E+06;3E+06;3.7E+06;3.7E+06;5E-02;5E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.37E-08;1.37E-08;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2E+06;2E+06;3.7E+06;3.7E+06;2.7E-02;2.7E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.7E-06;1.7E-06;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.59E-07;2.59E-07;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;9E-09;9E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.2E+06;2.2E+06;3.7E+06;3.7E+06;2E-02;2E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8.7E-09;8.7E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3E+06;3E+06;3.7E+06;3.7E+06;2.6E-02;2.6E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8E-06;8E-06;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.81E-05;2.81E-05;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8.62E-05;8.62E-05;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.6E-09;4.6E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);4E+06;4E+06;3.7E+06;3.7E+06;1.8E-02;1.8E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-09;3E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);5.1E+06;5.1E+06;3.7E+06;3.7E+06;1.6E-02;1.6E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;6.2E-09;6.2E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2E+06;2E+06;3.7E+06;3.7E+06;1.2E-02;1.2E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.6E-08;2.6E-08;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);7E+05;7E+05;3.7E+06;3.7E+06;1.8E-02;1.8E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1E-07;1E-07;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);2.9E+06;2.9E+06;3.7E+06;3.7E+06;2.88E-01;2.88E-01;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.43E-07;1.43E-07;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;5.38E-07;5.38E-07;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.6E-09;2.6E-09;3E-09;3E-09;10984492;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3.7E+06;3.7E+06;3.7E+06;3.7E+06;1E-02;1E-02;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_A;6.9E-07;6.9E-07;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient

with affinity taken from [17310065].;SP;2


3SE4_B_A;3.1E-07;3.1E-07;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;5.9E-07;5.9E-07;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;1.82E-06;1.82E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient

with affinity taken from [17310065].;SP;2


3SE4_B_A;3.33E-06;3.33E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;5E-06;5E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;2E-06;2E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;3.7E-06;3.7E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;2.56E-06;2.56E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;1.67E-06;1.67E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;2.94E-06;2.94E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;1.45E-06;1.45E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;8.7E-06;8.7E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;1.47E-06;1.47E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;4.17E-06;4.17E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;2.78E-06;2.78E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;5.88E-06;5.88E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;1.43E-06;1.43E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;3.23E-06;3.23E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_A;2.86E-06;2.86E-06;3E-08;3E-08;16171819;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;The crystal structure contains the YNS IFNa2 varient


3SE4_B_C;3E-09;3E-09;3E-09;3E-09;16171819;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3E+06;3E+06;3.666667E+06;3.666667E+06;9E-03;9E-03;1.1E-02;1.1E-02;;;;;The crystal structure contains the HEQ IFNa2 varient

the three mutations in the HEQ varient are on the opposite side of IFN2a from the IFNAR2 binding site

and have no affect on the kinetics or affinity of the interactions [17310065


3SE4_B_C;6.9E-10;6.9E-10;5E-10;5E-10;17310065;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1E+07;1E+07;1E+07;1E+07;6.9E-03;6.9E-03;5E-03;5E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_C;6.7E-10;6.7E-10;6.9E-10;6.9E-10;17310065;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1E+07;1E+07;1E+07;1E+07;6.7E-03;6.7E-03;6.9E-03;6.9E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_C;6.7E-10;6.7E-10;5E-10;5E-10;17310065;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1E+07;1E+07;1E+07;1E+07;6.7E-03;6.7E-03;5E-03;5E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_C;5E-10;5E-10;6.9E-10;6.9E-10;17310065;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);1E+07;1E+07;1E+07;1E+07;5E-03;5E-03;6.9E-03;6.9E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.9E-06;1.9E-06;3E-08;3E-08;17310065;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1E-07;1E-07;3E-08;3E-08;17310065;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);1.8E+05;1.8E+05;2E+05;2E+05;1.3E-02;1.3E-02;7E-03;7E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.1E-07;1.1E-07;3E-08;3E-08;17310065;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);1.6E+05;1.6E+05;2E+05;2E+05;1.7E-02;1.7E-02;7E-03;7E-03;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_C;5E-09;5E-09;5E-09;5E-09;16479007;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);3E+06;3E+06;3E+06;3E+06;1.5E-02;1.5E-02;1.5E-02;1.5E-02;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_C;8.57E-09;8.57E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-08;3E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-09;3E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.21E-09;2.21E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.35E-09;4.35E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.53E-09;3.53E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.61E-09;2.61E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.36E-08;1.36E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1E-08;1E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.31E-06;2.31E-06;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.3E-07;1.3E-07;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.43E-08;1.43E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.2E-04;1.2E-04;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;6E-06;6E-06;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8.82E-09;8.82E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;6E-09;6E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.16E-09;3.16E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.63E-09;2.63E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.84E-09;4.84E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-09;3E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.27E-09;2.27E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.29E-09;4.29E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.17E-09;4.17E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1E-07;1E-07;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.88E-08;1.88E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-07;3E-07;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3E-08;3E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_A;1.85E-06;1.85E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;3.41E-06;3.41E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;5.17E-06;5.17E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;2.03E-06;2.03E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;3.75E-06;3.75E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;2.63E-06;2.63E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.7E-06;1.7E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;3E-06;3E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.49E-06;1.49E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;8.82E-06;8.82E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.5E-06;1.5E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;4.29E-06;4.29E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;2.83E-06;2.83E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.46E-06;1.46E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;3.26E-06;3.26E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;2.94E-06;2.94E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;1.27E-06;1.27E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;3.33E-06;3.33E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;>3E-06;3E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;2.05E-06;2.05E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;2.31E-06;2.31E-06;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;7.04E-07;7.04E-07;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;3.18E-07;3.18E-07;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;6E-07;6E-07;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_A;5E-08;5E-08;2.5E-08;2.5E-08;21854986;Interferon alpha-2;Interferon alpha/beta receptor 1;298(assumed);;;;;;;;;;;;;Crystal structure is one of the mutants in the paper. This mutant is taken as 'wild-type';SP;2


3SE4_B_C;2.73E-08;2.73E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;5E-08;5E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;6E-08;6E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.5E-07;1.5E-07;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;6.52E-08;6.52E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;7.5E-09;7.5E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;9.68E-09;9.68E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8.11E-09;8.11E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4E-09;4E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.76E-09;4.76E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;4.62E-09;4.62E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;8.82E-09;8.82E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.76E-07;1.76E-07;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.26E-09;2.26E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.23E-09;3.23E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.4E-09;2.4E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;1.76E-08;1.76E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;3.75E-08;3.75E-08;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient


3SE4_B_C;2.54E-09;2.54E-09;3E-09;3E-09;21854986;Interferon alpha-2;Interferon alpha/beta receptor 2;298(assumed);;;;;;;;;;;;;The crystal structure contains the HEQ IFNa2 varient